STOCKHOLM—Prostate cancer patients with 2 or more adverse pathologic characteristics found at radical prostatectomy may benefit the most from adjuvant radiotherapy (aRT) in terms of reduced risk of cancer-specific mortality, researchers concluded in a poster presentation at the European Association of Urology 29th annual congress.
Firas Abdollah, MD, of the Henry Ford Health System in Detroit, and colleagues tested the effect of aRT on cancer-specific mortality (CSM) according to a risk score based on the number and nature of adverse pathologic characteristics, namely Gleason score 8-10, pT3b/4 disease, and lymph node invasion. The study included 7,616 patients with pT3/4 prostate cancer who underwent radical prostatectomy from 1995 to 2009. The investigators stratified patients according to risk score (less than 2 vs. 2 or more adverse characteristics).
Among patients with a risk score of 2 or more, those who underwent aRT had a significantly lower 10-year CSM rate than those who did not (6.9% vs. 16.2%). Ten patients would need to be treated with aRT to prevent one cancer-related death, according to the investigators. Results showed that aRT was not associated with lower CSM rates overall or among subjects with a risk score less than 2.